Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma.

Khamko, Ricuphan; Wasenang, Wiphawan; Daduang, Jureerut; Settasatian, Chatri; Limpaiboon, Temduang

Khamko, Ricuphan; Wasenang, Wiphawan; Daduang, Jureerut; Settasatian, Chatri; Limpaiboon, Temduang.

Afiliación

Khamko R; Biomedical Science Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand.
Wasenang W; Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.
Daduang J; Faculty of Medical Technology, Nakhon Ratchasima College, Nakhon Ratchasima, Thailand.
Settasatian C; Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.
Limpaiboon T; Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

In Vivo ; 36(3): 1168-1177, 2022.

Article en En | MEDLINE | ID: mdl-35478117

Asunto(s)

Neoplasias de los Conductos Biliares; Colangiocarcinoma; Neoplasias de los Conductos Biliares/tratamiento farmacológico; Conductos Biliares Intrahepáticos/metabolismo; Moléculas de Adhesión Celular/metabolismo; Colangiocarcinoma/tratamiento farmacológico; Colangiocarcinoma/genética; Proteínas Ligadas a GPI; Humanos; Pronóstico; Proteínas Proto-Oncogénicas; Proteínas Tirosina Quinasas Receptoras; Tirosina Quinasa del Receptor Axl

Palabras clave

AXL; AXL inhibitor R428; OPCML; enhancing agent; prognostic marker

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Colangiocarcinoma Tipo de estudio: Prognostic_studies Idioma: En Revista: In Vivo Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google